A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Key claim: This early-phase clinical trial evaluates the safety and tolerability of roginolisib (a PI3K-delta inhibitor) combined with ruxolitinib in myelofibrosis patients who are unresponsive to JAK inhibitor therapy.
Abstract
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.
Why this matters
JAK inhibitor-unresponsive myelofibrosis is a defining adverse natural-history milestone within PMF, marking patients with poor prognosis and limited options short of transplant. Adding a PI3K-delta inhibitor like roginolisib to ruxolitinib tests whether parallel pathway blockade can rescue or augment JAKi activity specifically in this subtype, expanding the PMF-specific combination therapy landscape.